GlassScriptPhysician profile
Kacy R Ramirez
NPI 1912585142
$12,788.63
in general payments reported to CMS, 2019-2025
41 companies · $2,655 in 2025
The $2,655 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,908 · 2022: $2,406 · 2023: $3,299 · 2024: $2,521 · 2025: $2,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,311 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,310.59 |
| Education | $163.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,725.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,238.11 | 2021-2025 | |
| Lilly USA, LLC | $1,630.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $613.47 | 2021-2025 | |
| Pfizer INC. | $605.69 | 2021-2025 | |
| Dexcom, INC. | $527.77 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $513.11 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $445.52 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $305.82 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $276.42 | 2021-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.73 | 2021-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $230.21 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $224.83 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $205.06 | 2022 | |
| Sumitomo Pharma America, INC. | $180.71 | 2024-2025 | Gemtesa |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $179.36 | 2021-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.49 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $174.94 | 2023-2025 | Cologuard Collection Kit |
| Nevro Corp. | $139.64 | 2022-2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $128.76 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Astrazeneca Pharmaceuticals LP | $105.16 | 2021-2025 | Breztri, Airsupra |
| Corcept Therapeutics | $92.67 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.57 | 2021-2025 | Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $87.56 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $72.39 | 2021-2023 | Belsomra |
| Shield Therapeutics INC | $71.41 | 2024-2025 | |
| Axsome Therapeutics, INC. | $58.67 | 2024 | Auvelity |
| Tris Pharma INC | $56.72 | 2023-2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $48.55 | 2021-2023 | |
| Lundbeck LLC | $45.60 | 2023-2024 | Rexulti |
| Ardelyx, INC. | $42.31 | 2024 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $36.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.11 | 2025 | Trintellix |
| Tolmar, INC. | $28.50 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $21.53 | 2021 | |
| Paratek Pharmaceuticals, INC. | $20.78 | 2023 | Nuzyra |
| Eisai INC. | $19.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.34 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $17.57 | 2024 | Voquezna |
| Medtronic, INC. | $16.39 | 2025 | Synchromedii |
| Impel Pharmaceuticals INC. | $14.63 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacy Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.